A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI

A Phase III, Open-Label, Randomized Multicenter Study to Compare AC0010 and Pemetrexed/Cisplatin in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI

A Phase III, Open-Label, Randomized Multicenter Study to Compare AC0010 and Pemetrexed/Cisplatin in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI.

Study Overview

• Status: Withdrawn
• Conditions: NSCLC
• Intervention / Treatment: Drug: AC0010; Drug: Pemetrexed; Drug: Cisplatin 75mg/m2

Detailed Description

This is a phase III, open label, randomized study assessing AC0010 (300 mg, BID) versus pemetrexed/cisplatin (4-6 cycles) in patients with advanced NSCLC, who have progressed following prior therapy with EGFR-TKI.

Patients must provide a biopsy for central confirmation of T790M mutation positive. Eligible patients will be randomized (2:1) into AC0010 group or pemetrexed/cisplatin group. Patients in chemotherapy group can cross-over to AC0010 treatment when patients experience disease progression or intolerability of chemotherapy. The primary objective of the study is to compare the PFS of AC0010 and pemetrexed/cisplatin.

• Study Type: Interventional
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Beijing, China, 100021
    • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
  • Beijing
    • Beijing, Beijing, China, 100000
      • Beijing Cancer Hospital
    • Beijing, Beijing, China, 100000
      • Peking Union Medical College Hospital
    • Beijing, Beijing, China, 100000
      • Chinese General PLA Hospital
  • Chongqing
    • Chongqing, Chongqing, China, 400000
      • Xinqiao Hospital Army Medical University
  • Fujian
    • Fuzhou, Fujian, China, 350000
      • Fuzhou General hospital of Nanjing Military Command
    • Fuzhou, Fujian, China, 350000
      • Fujian Cancer Hospital
  • Hebei
    • Shijiazhuang, Hebei, China, 050000
      • Tumor Hospital of Hebei Province
  • Heilongjiang
    • Harbin, Heilongjiang, China, 150000
      • Harbin Medical University Cancer Hospital
  • Henan
    • Zhengzhou, Henan, China, 450000
      • Henan Cancer Hospital
  • Jiangsu
    • Nanjing, Jiangsu, China, 210000
      • Jiangsu Province Hospital
    • Nanjing, Jiangsu, China, 210000
      • Nanjing General Hospital
  • Liaoning
    • Dalian, Liaoning, China, 116000
      • The Second Hospital of Dalian Medical University
    • Dalian, Liaoning, China, 116000
      • The First Affiliated Hospital of Dalian Medical University
    • Shenyang, Liaoning, China, 110000
      • The First Affiliated Hospital of China Medical University
  • Shanghai
    • Shanghai, Shanghai, China, 200000
      • Fudan University Shanghai Cancer Center
  • Sichuan
    • Chengdu, Sichuan, China, 610000
      • West China Hospital,Sichuan University
    • Chengdu, Sichuan, China, 610000
      • Sichuan Cancer Hospital & Institute
  • Tianjin
    • Tianjin, Tianjin, China, 300000
      • Tianjin Medical University Cancer Institute & Hospital
  • Zhejiang
    • Hangzhou, Zhejiang, China, 310000
      • Zhejiang Cancer Hospital
    • Hangzhou, Zhejiang, China, 310000
      • The First Affiliated Hospital,Zhejiang University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female, aged between 18-75 years old.
2. Histological or cytological confirmed diagnosis of locally or metastatic NSCLC (stage IIIB/IV).
3. Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy.
4. Radiological proven disease progression while on first generation EGFR TKIs.
5. At least one measurable disease according to RECIST 1.1.
6. Confirmation of tumor EGFR sensitive mutation positive in previous tumor samples, including G719X, exon 19 deletion, L858R, L861Q.
7. Confirmation of tumor harboring of T790M mutation by central lab with a biopsy sample taken after failure of first generation EGFR TKIs.

8. Adequate organ function:

   • Bone marrow reserve: Absolute neutrophil count ≥1.5 ´ 109/L,. Platelet count ≥100´ 109/L , Hemoglobin≥9 g/dL
   • Liver function: Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤2.5 × the upper limit of normal (ULN) or <5 times ULN in the presence of liver metastases; Total bilirubin ≤1.5 × ULN
   • Kidney function: Creatinine ≤1.5 × ULN
9. Anti-cancer treatment prior to EGFR TKIs including chemotherapy, radiotherapy and other anti-cancer drugs for advanced stage is not allowed.
10. Resolved toxicities from prior therapy less than CTCAE grade 1 (except alopecia) and minimum 7 days of washout period from previous erlotinib, gefitinib or icotinib.
11. ECOG performance status 0 to1.
12. Life expectancy more than 3 months.
13. Patients without CNS metastases or asymptomatic patients with brain metastases. End of local therapy for brain metastases, including radiotherapy and surgery is required ≥28 days prior to beginning of screening.
14. Provision of signed informed consent.

Exclusion Criteria:

1. Undiagnosed by pathology.
2. HCV antibody positive, active hepatitis B (hepatitis B virus carrier can be recruited)
3. HIV antibody positive, other acquired immunodeficiency disease and congenital immunodeficiency disease. Patients with organ transplantation.
4. Patients received new aided/aided system therapy with palindromia in 12 months, the new aided/aieded system therapy is considered to be previous first-line treatment.

5. Condition of organ system:

   • Large field radiation or radiation field covered more than 30% bone marrow within 4 weeks of enrollment.
   • A past history of interstitial lung disease, drug-induced interstitial lung disease or other active interstitial lung disease with clinical proof
   • Idiopathic pulmonary fibrosis (IPF).
   • In the investigator opinion, any severe or uncontrolled disease, such as unstable or uncontrolled respiratory, cardiovascular, liver or kidney diseases.
   • Any unstable system disease including refractory hypertension, unstable angina pectoris, congestive heart-failure, liver and renal disease, metabolic disease.
   • Patients with other malignant tumor in 5 years (except cured cervical carcinoma in situ, Basal cell carcinomas, squamous cell carcinoma)
   • A past history of neurological disorder or mental disorder including epilepsy and dementia.
   • Patients with chronic gastrointestinal diseases, inability to swallow medication, malabsorption syndrome or previous significant bowel resection that would preclude adequate absorption of AC0010.
6. Uncontrolled pleural and pericardial effusion.
7. Patients who have used high-dose glucocorticoids or other immunosuppressive agents within 1 month prior to screening.
8. Patient with symptomatic CNS metastases.
9. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 6 months, heart block with second degree or greater, QTcB > 430ms（male）or > 450ms（female）.
10. Patients receiving medication known to prolong QT interval and potent inducers and inhibitors of CYP3A4 within 4 weeks of fist dose of AC0010.
11. Patients prove 1ml plasma to site's central lab after signing informed consent and the test results show the medication of AZD9291.
12. Patients who have been registered and received the study treatment or withdrawn from the study cannot be enrolled.
13. Patients receive unrelated surgery more than 14 days prior to the screening.
14. Pregnant and lactating women.
15. Women with childbearing potential are defined as all women who are physiologically able to have a pregnancy, unless they are using an efficient contraceptive method during treatment and within 7 days after discontinuation of treatment.
16. Men who have sexual intercourse unless they use a condom during sexual intercourse during treatment and 7 days after discontinuation of treatment and do not impregnate their sexual partners during the period. Vasectomized males are also required to use condoms to prevent the transmission of drugs through semen.
17. Patients who are considered by the investigator as inappropriate to participate in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: AC0010; AC0010, 300mg, orally, BID with a 21-day cycle	Drug: AC0010; 300mg, orally, BID; Other Names: AC0010MA
ACTIVE_COMPARATOR: Chemotherapy; pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 on day one of 21-day cycle, with total of 4-6 cycles.	Drug: Pemetrexed; Pemetrexed will be administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. Folic acid will be administered 1-2 weeks prior to the 1st dose, then daily during the treatment period until 21days post the last dose. Vitamin B12 will be administered on the same day of pemetrexed infusion during the treatment period. Corticosteroid will be adminstered on the day prior to, on the day, and on the day after infusion.; Other Names: Alimta; Drug: Cisplatin 75mg/m2; Cisplatin will be administered as an intravenous infusion.; Other Names: cis-platinum

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival (PFS)	To assess the Progression-Free Survival (PFS) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC).	From the date of randomization until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 24 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR)	To assess the overall objective response rate (ORR) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC).	Baseline up to 28 days after completion of study drug, assessed up to 24 months.
Duration of Response (DoR)	To assess the overall objective response rate (ORR) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC).	From occurring of CR or PR until progression or the date of death from any cause, whichever came first, assessed up to 24 months.
Disease Control Rate (DCR)	To assess the Disease Control Rate (DCR) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC).	From the date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
Overall Survival (OS)	To assess the Overall Survival (OS) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC).	From the date of randomization to death or end of study, which is assessed up to 36 months.
Patient Reported Outcomes by EORTC QLQ-C30 Questionnaire	To assess the safety of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC).	Baseline up to 28 days after completion of study drug, assessed up to 24 months.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of toxicity, grading with CTCAE 4.03	Clinical chemistry, hematology, urinalysis, vital signs, physical examination, weight, ECG and ECOG Performance status and adverse event will be used to assess safety endpoints.	From the date of randomization until end of treatment,which is assessed up to 24 months

Collaborators and Investigators

• Sponsor: Hangzhou ACEA Pharmaceutical Research Co., Ltd.
• Collaborators: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Investigators: Principal Investigator: Yuankai Shi, MD., Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): December 1, 2018
• Primary Completion (ANTICIPATED): December 1, 2019
• Study Completion (ANTICIPATED): January 1, 2020

Study Registration Dates

• First Submitted: December 1, 2016
• First Submitted That Met QC Criteria: February 15, 2017
• First Posted (ACTUAL): February 20, 2017

Study Record Updates

• Last Update Posted (ACTUAL): February 4, 2019
• Last Update Submitted That Met QC Criteria: January 31, 2019
• Last Verified: January 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Molecular Mechanisms of Pharmacological Action; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Folic Acid Antagonists; Cisplatin; Pemetrexed; Abivertinib
• Other Study ID Numbers: AEGIS2:AC201602AVTN04

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No